Résultats de la recherche
10
Tout
TrainHealth Announces FDA Clearance of TrainFES Advanced, Improving Results in Neurological Rehabilitation
18 mars 2025 10h23 HE
|
TrainHealth
TrainHealth seeks to disrupt the neurological rehabilitation market with its new "TrainFES Advanced" device, which they announce has been cleared by FDA.
Bioxodes obtient la désignation de médicament orphelin pour son candidat-médicament dans le traitement de l’AVC hémorragique aux États-Unis et en Europe
05 mars 2025 02h30 HE
|
Bioxodes
La FDA et l’EMA accordent à BIOX-101 le statut de médicament orphelin pour traiter l’AVC hémorragiqueLe statut de médicament orphelin est susceptible d‘accélérer le développement et l’approbation du...
Bioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe
05 mars 2025 02h30 HE
|
Bioxodes
FDA, EMA grant BIOX-101 ODD status to treat intracerebral hemorrhagic stroke (ICH)ODD status may expedite drug candidate development and approvals BIOX-101 interim Phase 2a data in ICH imminent ...
Emboa Medical creates, validates novel catheter to improve stroke patients’ outcomes
18 févr. 2025 09h01 HE
|
Purdue Research Foundation
WEST LAFAYETTE, Ind., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Emboa Medical Inc., a medical device startup, has mimicked a snake’s evolutionary advantage to improve the retrieval of blood clots that cause...
Bioxodes obtient de nouveaux financements qui permettront de franchir les jalons début 2025 et de poursuivre son financement de Série B
12 févr. 2025 02h30 HE
|
Bioxodes
Bioxodes lève 2,7 millions d'euros auprès de ses investisseurs historiques dans le cadre d'une extension de la Série ADes données intermédiaires issues de l'étude de phase 2a sur l'hémorragie...
Bioxodes secures new funds to reach early 2025 milestones and pursue Series B financing
12 févr. 2025 02h30 HE
|
Bioxodes
Bioxodes raises €2.7 million from existing investors in Series A extensionInterim data from BIRCH intracerebral hemorrhage (ICH) Phase 2a trial in Q1 2025Recruitment of up to 16 additional patients...
Stroke Diagnostics Global Market Forecasts 2024-2034: Advancements in CT, MRI, and PET Scans and Growing Focus on Minimizing Long-term Stroke Impairment Fueling Growth
09 janv. 2025 10h26 HE
|
Research and Markets
Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "Stroke Diagnostics Market by Type, by Technology, by End User, and By Region" report has been added to ResearchAndMarkets.com's offering.The global...
Bioxodes atteint un premier objectif de recrutement pour l'essai de phase 2a sur l'hémorragie intracérébrale
19 déc. 2024 02h30 HE
|
Bioxodes
Bioxodes a recruté les 16 premiers patients pour l'essai de BIOX-101Une analyse intermédiaire sera réalisée à la fin du traitement de la première cohorte de patientsBIOX-101 est un candidat...
Bioxodes meets enrollment milestone in Phase 2a intracerebral hemorrhagic stroke trial
19 déc. 2024 02h30 HE
|
Bioxodes
Bioxodes has enrolled first 16 patients in trial with BIOX-101Completing treatment of first cohort of patients will trigger interim analysisBIOX-101 is a first-in-class drug candidate, a peptide...
RapidPulse Receives FDA Approval to Begin IDE Study in Ischemic Stroke Using Innovative Cyclic Aspiration System – Recently Completed Clinical Trial Shows Significantly Higher First Pass and Frontline Success Rates
11 déc. 2024 10h30 HE
|
RapidPulse, Inc
MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) -- RapidPulse, Inc., a Delaware corporation headquartered in Miami, Florida focused on improving the treatment success rate for acute ischemic stroke (AIS)...